Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
about
The role of BST-2/Tetherin in host protection and disease manifestationTargeted therapy for HM1.24 (CD317) on multiple myeloma cellsCombination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitorsThe novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathwaysGlycomic analysis of membrane glycoproteins with bisecting glycosylation from ovarian cancer tissues reveals novel structures and functionsBone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells.The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaCD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.Opportunities to exploit non-neutralizing HIV-specific antibody activity.Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesMonoclonal antibody-based immunotherapy for multiple myeloma.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.T cell-based targeted immunotherapies for patients with multiple myeloma.Targeting B-cell maturation antigen in multiple myeloma.Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis.A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.Immunotherapy Strategies Against Multiple Myeloma.
P2860
Q26752737-38DF04E2-5250-4538-B922-B8005F2079B8Q27026161-0319413C-4880-43BA-95A1-66910E887D6FQ28537997-20689E21-8330-4327-8DB1-4073004D1679Q33840201-CC52AE99-EB10-46A4-85DD-B01C6F5F7CB6Q34502870-F927F135-F39C-420F-A099-FE61F2C80CD4Q34807860-CE5AD2B5-FB0C-40E7-93BB-782B9340E20EQ34856178-3931CF4E-89BA-416D-A873-7C32D310B2FCQ35362935-B8CCB9A9-AF43-4DFB-BFD0-8BC32302FEE2Q35669068-AFB7DE81-4710-4FC1-88E7-BE952712331CQ35832168-64A799B6-F27A-44C0-9C4C-D9AFCAC6F45FQ36213431-394281B8-EB94-490D-94C3-D53A2239C0DAQ36546548-8D903FA6-E2C0-4515-AEAB-F14B705BAAA4Q37113941-C5257370-7C8C-40AE-9FD4-21F1B68D3B69Q37125759-C04BEA25-B4A3-46A3-912F-E3D4BF760051Q38050507-EBAF0E6E-F1B0-496D-B4E9-F17A28931902Q38074017-5AAE2C8C-04C0-4661-9A6E-517EE0EEA379Q38090691-061DF2A4-5F62-45AA-9018-A209715DF7ECQ38246639-A402511E-FDCD-47F9-AC4F-9C76CFCBAF3CQ38586922-FC6ACED3-78A0-4456-B7CE-D2D308822207Q38896842-D7ADD613-6405-412D-AD7B-3F8916852310Q42057546-2DF525D4-22B3-48BC-BB5D-9619FDC4E8E0Q45761043-9D6D0403-3DB5-415E-9CA5-B3CFA9BD9D33Q49995864-1266AF19-EE55-4767-8602-A1FACB442E50
P2860
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potent in vitro and in vivo ac ...... a augmented effector function.
@en
Potent in vitro and in vivo ac ...... a augmented effector function.
@nl
type
label
Potent in vitro and in vivo ac ...... a augmented effector function.
@en
Potent in vitro and in vivo ac ...... a augmented effector function.
@nl
prefLabel
Potent in vitro and in vivo ac ...... a augmented effector function.
@en
Potent in vitro and in vivo ac ...... a augmented effector function.
@nl
P2093
P2860
P1433
P1476
Potent in vitro and in vivo ac ...... a augmented effector function.
@en
P2093
Duc-Hanh T Nguyen
Greg A Lazar
Holly M Horton
Hsing Chen
John R Desjarlais
Matthew J Bernett
Nikhil C Munshi
Saso Cemerski
Seung Y Chu
P2860
P304
P356
10.1182/BLOOD-2011-06-364521
P407
P577
2012-01-13T00:00:00Z